A c-MET receptor and vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) used for the treatment of advanced kidney cancer. Savolitinib works by interfering with the growth of cancer cells and blocking the development of a new blood supply (angiogenesis) to the tumour, thereby starving the tumour of nutrients and oxygen needed to grow. Savolitinib is a type of angiogenesis inhibitor. Savolitinib is the chemical (or generic) name of the drug.

Share this Post!